About us Pricing ContactSubscribe

article Open AccessTop 1% cited

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

New England Journal of Medicine · 2020 · Vol. 382(20) · pp. 1894–1905

Richard S. Finn✉(UCLA Jonsson Comprehensive Cancer Center)Shukui Qin(Nanjing General Hospital of Nanjing Military Command)Masafumi Ikeda(National Cancer Center Hospital East)Peter R. Galle(Johannes Gutenberg University Mainz)Michel Ducreux(Université Paris-Saclay)Tae‐You Kim(New Generation University College)Masatoshi Kudo(Kindai University)В. В. Бредер(Russian Cancer Research Center NN Blokhin)Philippe Merle(Hôpital de la Croix-Rousse)Ahmed O. Kaseb(The University of Texas MD Anderson Cancer Center)Daneng Li(City of Hope)Wendy VerretDerek-Zhen Xu(Roche (China))Sairy HernandezJuan Liu(Roche (China))Chen Huang(Roche (China))Sohail Mulla(Roche (Canada))Yulei WangHo Yeong Lim(Sungkyunkwan University)Andrew X. Zhu(Massachusetts General Hospital)Ann‐Lii Cheng(National Taiwan University Hospital)

View via DOI Full-text PDF

Abstract

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT03434379.).

Hepatocellular Carcinoma Treatment and Prognosis Colorectal Cancer Treatments and Studies Cancer Mechanisms and TherapyAtezolizumabBevacizumabHepatocellular carcinomaMedicineOncologyInternal medicineCarcinomaCancerChemotherapyImmunotherapy

MeSH terms

BevacizumabAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleCarcinoma, HepatocellularHumansLiver NeoplasmsMaleMiddle AgedQuality of LifeSurvival AnalysisKaplan-Meier EstimateIntention to Treat AnalysisProgrammed Cell Death 1 ReceptorAntibodies, Monoclonal, Humanized

Funding

Citations

6,911

FWCI

509.07

field-weighted impact

References

28

Percentile

100%

vs. same field & year

Citations per year

Cited by

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

Hepatology · 2023 · 1,480 citations

MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma

Cancers · 2021 · 296 citations

Emerging Therapies for Hepatocellular Carcinoma (HCC)

Cancers · 2022 · 291 citations

Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment

Cells · 2020 · 489 citations

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Journal of Hepatology · 2021 · 1,517 citations

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Journal of Hepatology · 2021 · 3,953 citations

Cancer statistics, 2023

CA A Cancer Journal for Clinicians · 2023 · 16,277 citations

References

Sorafenib in Advanced Hepatocellular Carcinoma

New England Journal of Medicine · 2008 · 12,835 citations

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

Biochemical and Biophysical Research Communications · 2005 · 965 citations

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

The Lancet · 2018 · 5,305 citations

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Hepatology · 2018 · 4,515 citations

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

The Lancet Oncology · 2018 · 2,498 citations

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

CA A Cancer Journal for Clinicians · 2018 · 87,314 citations

Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma · Scinovex